It is hypothesized that anaemia contributes to the progression of renal disease via hypoxia and oxidative stress. These effects may stimulate the production of extracellular matrix by fibroblasts, increasing interstitial fibrosis and leading to tubular destruction. Recombinant human erythropoietin (r-HuEPO, epoetin) has antioxidative and anti-apoptotic properties, though these effects have yet to be demonstrated in renal cells. In theory, epoetin treatment might slow the progression of renal failure, not only by correcting anaemia but also via direct effects on tubular and vascular cell survival. Alternative hypotheses suggest, however, that epoetin could have negative effects on the kidney because of its vasoconstrictive action, which is independent of haemoglobin levels. Retrospective and prospective clinical studies clearly show that epoetin does not accelerate progression of renal disease, provided that blood pressure is well controlled. Some studies suggest that epoetin slows the progression of renal failure, although this remains a controversial issue, as all these studies have methodological limitations. Larger randomized controlled trials and metaanalysis of the existing trials are required to establish whether treatment of anaemia with epoetin can indeed slow the progression of renal disease.
Introduction
End-stage renal disease (ESRD) is a major health problem resulting in a considerable increase in morbidity and mortality, decrease in quality of life and a substantial cost from renal replacement therapies. Furthermore, over the past decade, the incidence of ESRD has steadily increased at an annual rate of ;6-8% in most European countries. Slowing the progression of renal failure thus appears to be a major therapeutic challenge for the coming years. To date, however, no consensus exists concerning whether the progression of renal failure is accelerated by anaemia, or whether timely and adequate anaemia management can delay disease progression.
Potential beneficial effects of epoetin on the kidney
The beneficial effects of treating renal anaemia with epoetin are well known. They include improved wellbeing and quality of life, increased physical ability and reduced left ventricular mass. Epoetin increases oxygen delivery to tissues and thus reduces hypoxia. However, it may have other beneficial effects at the cellular level, which go beyond increasing oxygen delivery. There is clear evidence that epoetin protects cells against oxidative stress and apoptosis. On the basis of this evidence, it may be hypothesized that, in the kidney, epoetin could protect tubular and endothelial cells, decrease extracellular matrix production and alleviate the consequences of interstitial fibrosis ( Figure 1 ). These effects could slow the progression of renal failure.
Evidence for protection against oxidative stress and apoptosis
Erythrocytes represent a major antioxidant component of the blood w1x. Their antioxidant effects are mediated through the glutathione system, through enzymes such as superoxide dismutase and catalase and through cellular proteins. These proteins are devoid of enzymatic activity, but can react with reactive oxygen species, such as low molecular weight proteins of the erythrocyte membrane, vitamin E or co-enzyme Q. Furthermore, erythrocytes can regenerate consumed redox equivalents through the pentose phosphate pathway, and through reduction of oxidized glutathione by glutathione reductase.
The ability of erythropoietin to promote survival of red blood cells via its own receptor has been clearly established, and appears to be mediated by at least two different pathways. First, the binding of erythropoietin to its receptor prevents caspase activation, and thus caspase-mediated degradation of the transcription factor GATA-1 (essential for survival of erythroblasts) w2x. Secondly, erythropoietin induces the expression of anti-apoptotic proteins such as Bcl-x L , a protein with a high degree of homology to Bcl-2 w3x. The increased synthesis of Bcl-x L is mediated by the activation of a pathway involving the binding of the transcription factor STAT 5 to the Bcl-x promoter w4x.
Recent data show that the anti-apoptotic effects of erythropoietin are not limited to red blood cells, and can be observed with other cell types expressing the erythropoietin receptor. In rodents, local or systemic administration of epoetin protects against a variety of brain injuries. In rats undergoing middle-cerebral artery occlusion, protection against brain injury by epoetin was associated with an inhibition of apoptosis w5,6x. In vitro, epoetin has also been shown to protect endothelial and vascular smooth muscle cells against apoptosis w7,8x. In theory, other cells that express the erythropoietin receptor, such as the proximal tubular cells and medullary collecting duct cells of the kidney w9x, could also be protected against apoptosis.
Potential effects of epoetin on interstitial fibrosis
Interstitial fibrosis plays a key role in the progression of renal failure, and is now recognized as the best prognostic marker of progression. In theory, epoetin could affect both the accumulation of extracellular matrix within the interstitium and the deleterious consequences of interstitial fibrosis on nephrons.
Hypoxia and oxidative stress are known to stimulate the production of extracellular matrix by fibroblasts in vitro. Collagen production by fibroblasts, including human renal fibroblasts, is increased due to hypoxia w10-13x. Hypoxia has also been shown to decrease the production of metalloproteases and increase the expression of the metalloprotease inhibitor TIMP-1, suggesting that it may slow the degradation of extracellular matrix w12x. Interestingly, the production of transforming growth factor-b (TGF-b) is stimulated by oxygen deprivation, although its role in mediating the effects of hypoxia on extracellular matrix production is controversial w10,12x.
Further evidence of the important role of oxidative stress in interstitial fibrosis comes from the finding that non-cytolytic doses of hydrogen peroxide stimulate collagen synthesis and TGF-b production. Lipid peroxidation products, which are produced in increased amounts in response to oxidative stress, also up-regulate collagen production w14-17x. In vivo, treatment of rats with antioxidants can protect against the development of interstitial fibrosis, while deprivation of antioxidants seems to have the opposite effect w16,18x. Since correction of anaemia with epoetin increases oxygen delivery to the kidney and decreases oxidative stress, it is likely to suppress some stimuli of extracellular matrix production.
The process that links interstitial fibrosis and a reduction in nephron number remains to be clarified. However, microvascular damage and hypoxia could play a central role in this process. Progressive loss of interstitial capillaries and interposition of extracellular matrix between peritubular capillaries and tubules could lead to ischaemic damage of tubular cells, tubular destruction and reduction in nephron number w19,20x. This hypothesis is supported by experimental studies showing a striking inverse correlation between the extent of interstitial fibrosis and the number of Anaemia could thus favour nephron loss by further decreasing oxygen supply to tubular cells. Anaemia also decreases the antioxidant potential of the blood, while reduction in nephron number increases the production of reactive oxygen species that may have direct or indirect deleterious effects on tubular cells. Recently, apoptosis has also been associated with the progressive loss of renal cells during progression of experimental renal diseases w24x. Another beneficial effect of administration of epoetin could thus be a direct protection against apoptosis of tubular cells expressing the erythropoietin receptor.
Potential harmful effects of epoetin on the kidney
Although the arguments that epoetin may protect the kidney are credible, it should be stressed that, so far, the only evidence of its antioxidative and antiapoptotic effects comes from non-renal tissues. No proof is available that epoetin has effects on renal oxidative stress or renal apoptosis, and no benefits on interstitial fibrosis have yet been demonstrated. Moreover, it has been suggested that epoetin could have deleterious effects on kidney function, especially if it is used at too high a dose.
There is evidence that epoetin has effects on the arterial wall, which can lead to vasoconstriction and hypertension, with potentially harmful effects on kidney function. This evidence comes from studies at the cellular level, and in animals and humans with both normal and failing kidneys.
Effects of epoetin on endothelial cells
Endothelial cells play a crucial role in the maintenance of normal kidney function, especially glomerular filtration. Endothelial and glomerular mesangial cells have erythropoietin receptors, which are up-regulated in the presence of epoetin (Figure 2 ). Epoetin induces proliferation of mesangial and epithelial cells, and stimulates angiogenesis. It also stimulates vasoconstriction, via a shift in the prostaglandin balance towards vasoconstrictive metabolites, an increase in endothelin-1 and inhibition of acetylcholine-induced vasodilation. Epoetin increases Ca 2q influx into glomerular mesangial cells via tyrosine kinase-dependent phosphorylationuactivation of phospholipase C-c1, leading to mesangial cell contraction w25x.
Vasoconstrictive effects in animal studies
In animal experiments, epoetin inhibits activation of nitric oxide synthetase and lowers production of endothelial nitric oxide w26,27x. This process can be inhibited by various drugs, including non-steroidal anti-inflammatory agents and calcium antagonists. For example, a study in nephrectomized rats showed that administration of epoetin led to marked increases in blood pressure and resting and stimulated cytosolic Ca 2q levels w27x. These abnormalities were ameliorated by calcium channel blockade with felodipine, which normalized cytosolic Ca 2q and increased vascular and renal nitric oxide synthetase expression.
Vasoconstrictive effects in healthy volunteers
Studies in human volunteers with normal kidney function support the hypothesis that epoetin has an indirect vasoconstrictive effect, impairing the synthesis of endothelial nitric oxide. In one such study, forearm blood flow was measured by strain gauge plethysmography. The normal endothelium-dependent vasodilation observed after acetylcholine administration was blunted by epoetin w28x. However, pre-treatment with the cyclo-oxygenase inhibitor indomethacin restored the vasodilatory response to acetylcholine when administered simultaneously with epoetin. This suggests that epoetin may stimulate release of cyclooxygenase-dependent endothelium-derived contracting factors.
Another study in volunteers with normal kidney function used telethermography to measure skin temperature in the leg, after injection of various substances into the pedal artery w29x. Epoetin reduced skin temperature dose-dependently, indicating vasoconstriction, while acetylcholine and nitroprusside increased the cutaneous temperature. Infusion of epoetin in association with acetylcholine reverted the increase in acetylcholine-induced vasodilation. In contrast, epoetin could not reverse nitroprussideinduced vasodilation, indicating an indirect effect of epoetin on vasoconstriction.
Endogenous erythropoietin and blood pressure
In patients with hypertension without renal dysfunction, there is evidence of an association between endogenous erythropoietin levels and blood pressure. This association is independent of haemoglobin concentration. In one study, patients with established essential hypertension showed a close correlation between erythropoietin levels (which were within the normal range) and systolic and diastolic ambulatory blood pressure w30x. However, no such correlation was found in subjects with borderline hypertension. Similarly, total peripheral resistance was correlated with erythropoietin levels in established but not in borderline hypertension. However, erythropoietin was inversely correlated with renal plasma flow in both established and borderline hypertension. In normotensive subjects, erythropoietin levels were not correlated with blood pressure, total peripheral resistance or renal plasma blood flow.
Effects on the vasculature in patients with renal failure
The effects of epoetin on the vasculature are difficult to study in patients with renal failure, as most patients receive drugs that interfere with endothelial function.
However, there is some evidence suggesting that epoetin has a significant effect on vascular resistance and blood flow. Partial correction of anaemia with epoetin is frequently associated with an increase in arterial pressure. In addition, haemodynamic studies showed that administration of epoetin to correct renal anaemia does not change mean arterial pressure, but is associated with increased arterial vascular resistance and decreased venous distensibility in the forearm and calf. This change is accompanied by a reduction in peripheral blood flow w31x.
A further study showed that glomerular filtration rate (GFR), renal blood flow and filtration fraction did not change from baseline during 3 months of epoetin therapy. However, the expected acute effect of the angiotensin-converting enzyme (ACE) inhibitor captopril in increasing renal blood flow was blunted by epoetin administration w32x.
Epoetin and progression of renal failure: evidence from animal and human studies
To summarize the arguments so far: there are biologically plausible mechanisms by which epoetin might protect against progression of renal failure, via antioxidative and anti-apototic effects. There are counter-arguments that epoetin could damage the kidney via its vasoconstrictive effects. However, these arguments based on in vitro and in vivo experiments should be considered in the light of what is known about the effects of anaemia and epoetin on the kidney from clinical studies.
Comparisons of the rates of progression of various types of kidney disease are unhelpful; there is no apparent relationship between the degree of anaemia and progression of renal disease. For example, tubulointerstitial disease is characterized by severe anaemia, yet usually has a slow rate of progression. Diabetic nephropathy is characterized by both severe anaemia and fast progression. Polycystic kidney disease has less severe anaemia, yet progresses rapidly.
However, the crucial question is whether administration of epoetin has a positive, negative or neutral effect on progression of renal failure. Studies in animal models of renal failure initially led to concern about negative effects of epoetin. A study in subtotally nephrectomized rats found that the transglomerular pressure gradient was higher in epoetin-treated nonanaemic animals than in non-epoetin-treated anaemic animals w33x. Epoetin-treated animals exhibited more progression of proteinuria and sclerosis compared with the untreated rats, suggesting that anaemia is a haemodynamically favourable adaptation to chronic renal disease and that its overly vigorous correction may have adverse renal haemodynamic and structural consequences. However, this experiment was confounded by hypertension. In a second study in the rat remnant kidney model, progressive glomerular injury was no longer seen when hypertension was controlled, despite compensatory glomerular hyperfiltration and hypertrophy w34x.
Retrospective clinical studies
In humans, retrospective studies comparing renal function before and after epoetin treatment have found no evidence that epoetin therapy accelerates the progression of renal failure w35-39x. The majority of these studies found that renal function remained the same after epoetin treatment compared with the pre-treatment period. One study suggested a beneficial effect of anaemia correction on the rate of renal function decline w39x, but this effect was not statistically significant.
Recently, a small retrospective study did show a statistically significant slowing in the rate of decline of kidney function and delayed need for maintenance dialysis with epoetin treatment w40x. The study included 20 epoetin-treated patients and 43 non-anaemic controls who did not receive epoetin. Slowing of progression (measured as change in creatinine clearance) was observed in 10 of the epoetin-treated patients, whereas the other 10 showed no change in their rate of decline (P-0.05 compared with controls). Mean time until the start of dialysis was 16.2 months in the epoetin-treated group, compared with 10.6 months in the non-anaemic untreated controls group.
Prospective randomized trials
Interesting though the findings from retrospective studies are, authoritative answers to the question of whether epoetin affects the rate of progression of renal disease can only come from prospective randomized trials. To date, three such trials have been reported, though all were relatively small w41-43x. The US Recombinant Human Erythropoietin Predialysis Study Group studied 117 patients with anaemia of chronic renal failure who were not yet on maintenance haemodialysis w41x. Three doses of intravenous epoetin (50, 100 or 150 IUukg three times weekly) were compared with placebo over 2 months. Renal function was expressed in terms of serum creatinine and the reciprocal of serum creatinine. There was a decline in renal function in the 100 IUukg group (probably due to an outlier), but no change in the other two dose groups. Therefore, it was concluded that there was no evidence that epoetin therapy accelerated the decline in renal function.
A second study was conducted by Roth et al. w42x in 83 patients with severely impaired renal function, randomized to either no anaemia correction or to epoetin 50 IUukg subcutaneously three times weekly. GFR was measured by w 125 Ixiothalamate clearance, and patients were followed up for 48 weeks. GFR did not differ significantly between the two groups: the mean decline in GFR was 2.1 mlumin in epoetintreated patients vs 2.8 mlumin in untreated patients. This large-scale, open-label, multicentre study therefore showed no evidence that progression of renal failure is either accelerated or delayed by epoetin treatment. However, the trend was towards less decline in epoetin-treated patients, especially during the second half of the study when there was a 67% difference.
The most recent prospective randomized trial on the effects of epoetin on progression of renal anaemia was conducted by Kuriyama et al. w43x in 73 patients with moderate to advanced chronic renal insufficiency. The primary end-point for each patient was a doubling of the baseline serum creatinine. This yielded cumulative renal survival rates which were plotted against time (Figure 3) . Serum creatinine doubled in 26 (84%) untreated anaemic controls compared with 22 (52%) epoetin-treated controls and 21 (60%) non-anaemic controls. The cumulative renal survival rates in epoetintreated patients and non-anaemic controls were significantly better than those in anaemic controls. This study suggests that reversal of anaemia by epoetin treatment may delay the progression of renal failure, provided that blood pressure and rate of increase in haematocrit are controlled, and dietary protein restriction is adequate.
A recently reported retrospective observational cohort study of 5398 incident ESRD patients showed that epoetin improves survival in pre-ESRD patients before starting dialysis w44x.
Limitations of studies
Most of the studies conducted so far have major limitations. Type II errors (accepting the null hypothesis that there is no difference when in fact there is a difference) are highly likely, due to small sample size. It is notable that even the largest prospective studies contained only just over 100 patients. This may be contrasted, for example, with major cardiovascular trials, which typically have employed samples of thousands of patients to demonstrate small but statistically significant and clinically relevant effects of various treatments.
Informative censoring (selective drop-out) probably also occurred. There may be a delay in treatment benefit, which might only be observed in long-term studies. Studies to date have been conducted mainly in patients with relatively advanced disease, many of whom would be on dialysis according to present-day practice. Some studies have also failed to control for confounding factors such as blood pressure, lipids, ACE inhibitors and dietary protein.
Conclusions
There are plausible biological mechanisms by which anaemia could accelerate the progression of renal disease, by increasing the risk of hypoxia and oxidative stress in the kidney. These effects could contribute to interstitial fibrosis, ultimately leading to destruction of tubular cells. Epoetin treatment could, in theory, delay progression of renal disease, not only via correction of anaemia, but also by its antioxidative and antiapoptotic effects. Alternative hypotheses suggest, however, that epoetin could have negative effects on the kidney via its vasoconstrictive action, which is independent of haemoglobin levels.
In practice, retrospective and prospective clinical studies provide convincing evidence that there is no deleterious effect of epoetin on the rate of progression of renal disease, provided that blood pressure is well controlled. Indeed, there are indications that epoetin use actually slows the rate of disease progression and improves survival. However, the question of whether epoetin has a beneficial rather than a neutral effect remains open. The existing evidence from randomized controlled trials indicates possible benefits, but is inconclusive. Larger randomized controlled trials, anduor a meta-analysis of the existing trials, are required to establish with greater certainty whether treatment of anaemia with epoetin slows the progression of renal disease.
